Pasko,deborah cv.04.14 for linkedin pdf

DEBORAH A. PASKO, PHARMD, MHA
dag0415@gmail.com
Curriculum Vitae
ADDRESS
Office University of Michigan Health System
300 N. Ingalls
NIB 4D18, SPC 5475
Ann Arbor, MI 48109-5475
Telephone: (734) 936-9387
E-mail: dapasko@med.umich.edu
Residence: 573 Landings Blvd
Ann Arbor, MI 48103
Mobile # 734-497-6988
Email: dag0415@gmail.com
Licensure: State of Michigan
License # 5302031606
EDUCATION
09/2008 – 02/11 Masters of Health Administration
Walden University
School of Health Sciences
Minneapolis, MN
2001-2003 Nephrology/Critical Care Fellowship
College of Pharmacy
University of Michigan
Preceptor: Bruce A. Mueller, PharmD
1998-2001 Doctor of Pharmacy
College of Pharmacy
Idaho State University
1989-1995 Bachelor of Science, Pharmacy
College of Pharmacy
Ohio Northern University

Deborah A. Pasko, PharmD, MHA
2
EMPLOYMENT
EXPERIENCE
1/2012-present Clinical Specialist and Sr. Project Manager for Administration
Children’s and Women’s Administration
CS Mott Children’s Hospital and Von Voigtlander Women’s Hospital
University of Michigan Health System
05/15-present Intermittent Consultant, Medication safety
Joint Commission Resources
Oakbrook Terrace, IL
09/2009 – present LEAN coach
C.S. Mott Children’s Hospital and Von Voigtlander Women’s Hospital
Mott Administration Team
University of Michigan Health System, Ann Arbor, MI
09/2008-present Adjunct Clinical Associate Professor
Department of Clinical Sciences
University of Michigan, College of Pharmacy, Ann, Arbor, MI
05/2009 – 12/2011 Project Manager, Children’s and Women’s Replacement Hospital Project
C. S. Mott Hospital Administration Team
C. S. Mott Children’s Hospital and Von Voigtlander Women’s Hospital
03/2004-05/2009 Clinical Coordinator, Mott Pharmacy
C.S. Mott Children’s Hospital
Department of Pharmacy Services
09/2003-05/2009 Clinical Pharmacy Specialist, Pediatric Critical Care
Department of Pharmacy Services
07/2003 – 09/2008 Adjunct Clinical Assistant Professor
College of Pharmacy
University of Michigan, Ann Arbor, MI
09/2001-07/2003 Clinical Instructor
College of Pharmacy
University of Michigan, Ann Arbor, MI

3
12/1997-8/2003 Pediatric Pharmacist
C.S. Mott Children's Hospital
09/1997-11/1997 Staff Pharmacist
St. Joseph’s Mercy Hospital, Ann Arbor, MI
08/1995-09/1997 Staff Pharmacist
St. Rita’s Medical Center, Lima, OH
06/1992-08/1995 Pharmacy Intern
St. Rita’s Medical Center, Lima, OH
LEADERSHIP TRAINING
09/2013 – 05/2014 Advanced Leadership Program
Center for the Advancement of Women
University of Michigan
08/2013 OCHSPS Wave 2 Error Prevention and Leadership Methods
Ohio Collaborative Hospitals Solutions for Patient Safety
Riley Children’s Hospital
Indianapolis, IN
05/2013 Leadership Essentials
5 day course for leaders at UMHS
02/2013 UMHS Conference: Developing Leaders and the Best
One day conference
Ann Arbor, MI
09/2009 LEAN Healthcare Course
University of Michigan Health System Quality Improvement
http://www.med.umich.edu/i/quality/edu/healthcare_course.html
10/2008 Manager’s Bootcamp
One day symposium: 13th
Annual American Society of Health System Pharmacy
Chicago, IL
Addressing Key Issues in Health-System Pharmacy: Spotlight on Leadership
Two day conference: 10/20-10/21/2008
10/2007 Management Skills for New Clinical and Operational Leaders

4
One day symposium: 12th
Annual American Society of Health System Pharmacy
Chicago, IL
10/2007 Scanning the Radar of Health-System Pharmacy: Developing Strategies and
Tools for Successful Leadership
Two day conference: 10/15-10/16/2007
01/2005 – 03/2005 The Edge: Foundations for Successful Leadership
10 week course for new managers and supervisors
TECHNICAL TRAINING
05/2013 Epic Willow Fundamentals
3 day course
Epic Headquarters
Verona, Wisconsin
03/2013 Epic Beacon Fundamentals
2 day course
Epic Headquarters
Verona, Wisconsin
02/2013 Epic Inpatient Fundamentals
3 day course
Epic Headquarters
Verona, Wisconsin
C&W HOPSITAL ADMINISTRATION
SR. PROJECT MANAGER AND CLINICAL SPECIALIST RESPONSIBILITIES (CURRENT)
Health System:
 Project Manager, MiChart, Children’s and Women’s Hospitals (C&W) , University of Michigan
Hospital and Health Systems
 Work closely with all medical disciplines to transition the inpatient areas into the new
MiChart, Epic system
 Facilitate pediatric oncology and BMT MiChart work and deadlines
 Adoption network and change facilitator
 Subject Matter Expert (SME) for Children’s and Women’s administration team
 Leader for pediatric medication management and Beacon inpatient workflow
 Committees: UMHS MiChart Leadership team, BCMA, Communications, Medication
Advisory Council, Beacon order set build and review, MiChart Change Network
 Administrative expert for Joint Commission initiatives, policies and procedures

5
 Project lead for MedEx 3500 syringe pump updates and pushes
 Project co-lead for C&W implementation of CareFusion large volume IV pumps
 Assist Associate Hospital Director with hospital emergency preparedness
Administrative:
 Work closely with Executive Director, Associate Hospital Director, and Nursing Director to set
hospital goals, short and long term strategy, and manage day to day operations
 Member of the C&W leadership team that guides our current strategic goals: Quality and
Safety, Access, Capacity and Staffing, Financial Stewardship, and MiChart
 This team reviews all monthly hospital metrics including financial status reports
 Administrative liaison for MCIT (including Secondary Alert Notification System), Biomed,
Pharmacy services, Laboratory, Radiology, Respiratory Care, Survival Flight/SWAT, ECMO,
other clinical support departments
 Participate in UMHS Hospital Administrator on-call (AOC) support
Clinical:
 Oversee, facilitate, or support all clinical initiatives within the Children’s and Women’s
Hospitals
 Continued clinical support for Eclipsys and Centricity systems
 Oversee and facilitate clinical initiatives with adult patient areas in the Children’s and
Women’s Hospital such as Adult Bone Marrow Transplant, Adult Leukemia, two adult surgical
services
 Administrative lead for CPR/RRT response in C&W, including adult response
Quality and Safety:
 Safety co-lead, C&W
 Secondary facilitator daily safety huddle
 Lead, participate, facilitate Ohio Collaborative HAC groups such as Adverse Drug Events
(ADE), Serious Safety Events (SSE’s), Ventilator Associated Pneumonia (VAP), Central
Line Associated Blood Stream Infections (CLABSI)
 Participate in all serious safety event reviews
 Member of safety scoring team, medication and non-medication events
 Administrative lead for pilot huddle initiative on ADE work within daily management
huddle for PICU
 Chair, Pediatric Medication Safety Committee, subcommittee of P&T
 Michigan Health Administration (MHA) safety round-table participant
LEAN
 Lead, facilitate, participate clinical LEAN initiatives
 Member of all LEAN coach committee, Michigan Quality Services
 Current projects:
1. Bed placement and throughput document for C&W hospital (lead)
2. Use of fluoroscopy for ECMO cannulation (lead)
3. Standardization of continuous infusion concentrations between C&W, UH,
CVC, and OR’s (co-lead)
4. Improving timing of antibiotic administration for fever and neutropenia
patients in the emergency room (co-lead)
5. Continual work on the ideal patient experience (group coaches)

6
6. Continual work on daily management huddles in various areas (pharmacy,
PICU)
INTERMITTENT CONSULTANT, MEDICATION SAFETY (CURRENT)
JOINT COMMISSION RESOURCES AND JOINT COMMISSION INTERNATIONAL
 Work with collaborative team to evaluate and recommend medication safety techniques to
clients, both domestic and international
 Mock surveyor
 Co-presenter of IV safety medication workshop
 Have now completed 2 day workshop in India (Mumbai, Pune, Kolkata, Hyderbad) and
Barranquilla Colombia
 Evaluate all aspects of medication safety including prescribing, procurement, dispensing, and
administration for clients
 Use and teach safety evaluation techniques such as RCA, FMEA, HPI tools in safety analyses
for clients
PROJECT MANAGER RESPONSIBILITIES FOR OPENINING OF NEW HOSPITAL
(2009-2011)
 Oversaw and facilitated operational and activation planning of the following areas for the CS
Mott Children’s and VonVoigtlander Women’s Replacement Hospital:
 Pediatric Intensive Care Unit
 Pediatric Cardiothoracic Intensive Care Unit
 Neonatal Intensive Care Unit
 Pediatric Hematology/BMT area
 Adult BMT area
 Operating Room and Recovery area
 EEG
 Pharmacy
 Respiratory Therapy
 Adult Services
 Extracorporeal Membrane Oxygenation Therapy Team
 Emergency/Disaster Management
 CPR and RRT
 Adult Services
 Regional Infectious Containment Unit
 Departmental lead for IT meetings (helped IT decide design, device types (telecom,
computers), and other IT needs for each department listed above)
 Leader of replacement hospital projects including unified communications, bedside
medication delivery, pharmacy medication managers, electronic nursing flow sheet, bedside
bar-coding medication administration, workforce planning, and hospital simulations
 Frequent presenter at town hall meetings

7
 Meet with hospital leadership team to keep abreast of new hospital projects and project
status
 Moved in new facility 12/4/2011
CLINICAL COORDINATOR RESPONSIBILITIES &
ACCOMPLISHMENTS
(2004-2009)
 Position 80% clinical, 20% operational
 Primary library builder and implementation lead for MedEx 3500 syringe pump initiative
 Responsible for staff pharmacist education and development
Oversee Patient Focused Care (PFC) pharmacists including performance evaluation
 Liaison between staff and clinical pharmacists
 Eliminated the “Rule of Six” and implemented standard concentrations in all pediatric patient
care areas including the intensive care areas: Pediatric Cardiothoracic (PCTU), Pediatric
Intensive Care (PICU), Neonatal Intensive Care (NICU), Trauma Burn Intensive Care (TBICU)
 Created and implemented smart technology syringe pumps in all pediatric patient care areas
 Developed protocols including: Pediatric/Neonatal Electrolyte Protocol, Factor Seven
Guidelines, Continuous Insulin Infusions, Continuous Heparin Infusions
 Pediatric clinical lead of “order sets” for our physician ordering system
 Responsible for all pharmacy aspects of Continuous Renal Replacement Therapies for both
adult and pediatric patients. This includes development of order forms, anticoagulation
protocols, and purchasing and implementation of a commercial standard dialysate solution
 Active role in Pediatric Medication Safety Committee and Med/Surgical Joint Practice
PEDIATRIC INTENSIVE CARE (PICU) SPECIALIST
RESPONSIBILITIES & ACCOMPLISHMENTS
(2003-2009)
 Participate in PICU multidisciplinary team daily rounds
 Pharmacy consult for pediatric trauma burn patients
 Develop and tailor pharmacotherapy regimens, goals, and assess outcomes for PICU patients
 Extensive experience in pediatric patients supported by Extracorporeal Life Support (ECLS),
Continuous Renal Replacement Therapies (CRRT), Intermittent hemodialysis, and
Extracorporeal Liver Support (ELMO)
 Extensive experience with pediatric cardiothoracic patients
 Provide drug information relating to the PICU questions for nurses, physicians, pharmacists
 Direct all pharmacokinetic monitoring for PICU patients
 Document clinical interventions/recommendations in U of M pharmacy clinical computer
program
 Participate in weekly PICU grand round discussions, including journal club, fellow rounds, and
monthly M&M

8
 Monthly orientation for medical students and residents
 Pharmacy lead for PICU “order sets” for computer physician ordering system
 Eliminated “Rule of Six” and implemented standard concentrations in the PICU
 Created and implemented smart technology syringe pumps in the PICU
 Developed sedation guidelines for the PICU
 Created guidelines for the use of dexmedetomidine
 Care for hematology/oncology and BMT patients transferred to the PICU
 Care for transplant patients (kidney, liver, heart)
PUBLICATIONS
Long, MT, Wagner D, Maslach-Hubbard A, Pasko DA, Baldridge P, Annich, GM.
Safety and efficacy of recombinant activated VII for refractory hemorrhage in
pediatric patients on extracorporeal membrane oxygenation: as single center
review. Perfusion 2013: DOI: 10.1177/0267659113499782.
Mueller BA, Jasiak KS, Thiel SR, Stevenson JM, Vilay AM, Scoville BA, Churchwell
MD, Pasko DA, Perkins N. Vibration enhances clearance of solutes with varying
molecular weights during in vitro hemodialysis. ASAIO Journal. 59(2):140-4,
2013.
Dickinson CJ, Wagner DS, Shaw BE, Owens, TA, Pasko DA, Niedner, MF. A
Systematic Approach to Improving Medication Safety in a Pediatric Intensive
Care Unit. Critical Care Nursing Quarterly 2012;35:15-26.
Wagner D, Pasko D, Phillips K, Waldvogel J, Annich G. In Vitro Clearance of
Dexmedetomidine in Extracorporeal Membrane Oxygenation. Perfusion
2012;28:40-46
Pasko DA, Churchwell MD, Salama NN, Mueller BA. Longitudinal Hemodiafilter
Performance in Modeled Continuous Renal Replacement Therapy. Blood
Purification 2011;32:82-88.
Matzke GR, Aronoff CR, Atkinson AF Jr, Bennett WM, Deckers BS, Edkardt KU,
Golper T, Grabe DW, Kasiske B, Keller F, Kielstein JT, Mehta R, Mueller BA,
Pasko DA, Schaefer F, Sica DA, Inker LA, Umans JG, Murray P. Drug Dosing
Consideration in patients with Acute and Chronic Kidney Disease-A Clinical
Update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney
International 2011;80(11):1122-37.
Wagner, D, Pasko D, Glenn D, Lapinski J, Callow L, Shaw B. The Medication
Manager: Results of a Medications at the Bedside Pilot in a Pediatric Teaching
Institution. Journal of Patient Safety 2010;6(2):76-79.

9
Pasko, DA, Churchwell MD, Btaiche IF, Jain J, Mueller BA. Continuous
Venovenous Hemodiafiltration Trace Element Clearance in Pediatric Patients: A
Case Series. Pediatric Nephrology 2009; 24:807-13.
Churchwell MD, Pasko DA, Smoyer WE, Mueller BA. Enhanced Clearance of
Highly Protein Bound Drugs by Albumin-Supplemented Dialysate During
Modeled Continuous Hemodialysis. Nephrology, Dialysis and Transplant
2009;24:231-8.
Kaakeh Y, Phan H, DeSmet B, Pasko, DA, Glenn DK, Stevenson JG. Enhanced
photoemission spectroscopy for verification of high-risk i.v. medications.
American Journal of Health-System Pharmacy 2008;65:49-54.
Taber SS, Pasko DA. The epidemiology of drug-induced disorders: the kidney.
Review. Expert Opinon on Drug Safety 2008;7:679-90.
Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, Pasko
DA, & Smoyer WE. (2007). Drug Prescribing in Renal Failure: Dosing Guidelines
for Adults and Children. 5th
edition. Philadelphia. American College of
Physicians.
Churchwell MD, Pasko DA, Btaiche IF, Jinesh JC, Mueller BA. Trace elements
removal during in vitro and in vivo continuous hemodialysis. Nephrology
Dialysis Transplantation 2007;22:2970-2977.
Cornell T, Wyrick P, Fleming G, Pasko DA, Han Y, Custer J, Haft J, Annich G. A
case series describing the use of argatroban in patients on extracorporeal
circulation. ASAIO Journal 2007;53:460-463.
Churchwell MD, Pasko, DA, Mueller BA. Daptomycin transmembrane
clearance in continuous hemofiltration and continuous dialysis with two
different hemodiafilters. Blood Purification 2006;24:548-554
McBryde KD, Bunchman TE, Kudelka TL, Pasko DA, Brophy P. Hypertonic
solutions in continuous renal replacement therapy for hyperosmolar acute
renal failure. Pediatric Critical Care Medicine 2005;6:220-225.
Nakamura AT, Btaiche I, Pasko DA, Jain JC, Mueller BA. In vitro clearance of
trace elements via continuous renal replacement therapy. Journal of Renal
Nutrition 2004 ;14 :214-219.
Swartz R, Pasko DA, O’Toole J, Starmann B. Improving the delivery of
continuous renal replacement therapy using regional citrate anticoagulation.
Clinical Nephrology 2004;61:134-143.

10
Kraft MD, Pasko DA, DePestel DD, Ellis JJ, et al. Clearance of linezolid during
continuous veno-venous hemodiafiltration. Pharmacotherapy 2003;23:1071-
1075
Mueller BA, Pasko DA, Sowinski KM. Higher renal replacement therapy dose
delivery influences on drug therapy. Artificial Organs 2003;27:808-814
Pasko DA, Mottes TA, Mueller BA. Pre-dialysis of blood prime in pediatric CRRT
normalizes pH and electrolyte content. Pediatric Nephrology 2003;18:1177-
1183
Flynn JT, Pasko DA. Calcium Channel Blockers: Pharmacology and place in
therapy
of pediatric hypertension. Pediatric Nephrology 2000;15:302-316
Letters
Churchwell MD, Btaiche IF, Pasko DA, Mueller BA. Reply letter: Trace elements
removal during in vitro and in vivo continuous hemodialysis. Nephrology
Dialysis Transplantation 2007;22:2970-2977.
Mueller BA. Pasko DA. Sowinski KM. Ofloxacin clearance during continuous
hemofiltration. [Comment. Letter] American Journal of Kidney Diseases
2003;42(6):1326-7; author reply 1327-8, 2003 Dec.
HOSPITAL COMMITTEES
2012-present MiChart Leadership Team, phase 3 (MLT3), UMHS
2013-present Medication Advisory Committee (MAC), MiChart, UMHS
2013-present Bedside Barcode Medication Administration Committee, MiChart, UMHS
2013-present Beacon Orders Group, MiChart, UMHS
2012-present MiChart operational committee, Chair, C&W
2012-present Secondary Alert Notification Systems (SANS Steering and Operational
Committee, Chair, C&W)
2012-present Quality and Safety Committee, C&W
2011-present CPR committee, C&W
2009-present Pediatric Medication Safety Committee, Chair, C&W
2009-present Adult Medication Safety Committee, UMHS
2004-present Pediatric Medical and Surgical Joint Practice Committee, UMHS
2010-2011 Bedside Barcode Medication Administration Committee, UMHS
2004-2009 Pediatric Medication Safety Committee, CS Mott Children’s Hospital
2003-2009 Pediatric Critical Care Joint Practice Committee, UMHS
2000-2012 Dialysis Standardization Committee, UMHS
1998-2001 Quality Improvement, UMHS
2000-2001 Chemo Focus Group, UMHS
1995-1997 Co-author; Pharmacy Newsletter, St. Rita's Medical Center

11
Professional
2000-2001 Membership Committee, Pediatric Pharmacy Advocacy Group
PRESENTATIONS
07/2013 “Improving IV Medication Practices for Patient Safety”
Invited Co-Speaker, Joint Commission International
Four, 2 day workshops
Mumbai, Pune, Kolkata, and Hyderbad, India
10/2007 – present “Drug Adsorption and Distribution Challenges during ECMO”
Invited speaker, UMHS ECMO lecture series
Ann Arbor, MI
06/2011 “Pediatric Medication Committee: Not Just Another Committee”
Invited Speaker, ASHP summer conference
Denver, CO
04/2011 “Drug Dosing in Pediatric CKD/AKI Patients”
Invited Speaker, National Kidney Foundation conference
Las Vegas, NV
05/2009 “Calculating Drug Doses in AKI. Drug Prescribing in Kidney Disease – Initiative
for Improved Dosing”
Invited Speaker, KDIGO (Kidney Disease Improving Global Outcomes
conference)
Baltimore, MD
04/2008 "Safe Medication Administration-Titration, Loading doses and Avoiding
Mistakes”
Invited speaker, Pediatric Nursing 2008-Providing a Continuum of Care
Ann Arbor, MI
02/2007 “Sedation in Children: From the Intensive Care Unit to Your Local Pharmacy”
Invited speaker, Michigan Pharmacist Association
Dearborn, MI
09/2005 “Pediatrics: Initiation Concerns and Pharmacy”
Invited speaker, Midwest CRRT conference
Indianapolis, IN
03/2005 “The Five Pillars of Pediatric Continuous Renal Replacement Therapy”
Invited speaker, Pediatric Grand Rounds, University of Michigan Health System
Ann Arbor, MI

12
12/2004 “Anticoagulation Options for Continuous Renal Replacement Therapy”
Invited speaker American Society of Hospital Pharmacists
Orlando, FL
10/2004 “Anticoagulation Issues in Continuous Renal Replacement Therapy”
Invited speaker American College of Clinical Pharmacy
Dallas, TX
10/2004 “Longitudinal Solute Clearance in an In Vitro Continuous Hemofiltration Model”
Invited Speaker, Platform Presentation
American College of Clinical Pharmacy, Dallas, TX
10/2004 “Anticoagulation for CRRT”
Invited speaker
Toronto, Ontario, Canada
09/2004 “CRRT in Children: They’re Not Just Small Adults”
Invited speaker Midwest CRRT Symposium
Indianapolis, IN
07/2004 “Drug Dosing and Nutrition in Pediatric Continuous Renal Replacement
Therapies”
Invited speaker 3rd
International Conference on Pediatric Continuous Renal
Replacement Therapy
Orlando, FL
05/2003-05/2009 Pharmacokinetics : A one-hour lecture for pediatric critical care fellows
10/2003-05/2009 “CRRT”, Monthly PICU resident rounds
09/2002 Nephrology Noon conference: Drug dosing in the elderly
03/2002 “Everything you always wanted to know about dialysis but did not know who to
ask”
An one-hour lecture for pharmacy staff and students.
07/2000 & 2001 "The Ins and Outs of Proper Order Writing"
A one-hour lecture for residents/medical students.
PROFESSIONAL

13
AFFILIATIONS
2000-present American Society of Health-System Pharmacists
2002-present Critical Care Medicine
2001-2008 American Society of Nephrology
1998-present Pediatric Pharmacy Advocacy Group
AWARDS
2009 Pharmacy Practice Research Literature Award
American Society of Hospital Pharmacy
2005 Pharmacist of the Year
Southeastern Michigan Pharmacist Society
2003 Bayer Critical Care Fellow
American College of Clinical Pharmacy
TEACHING EXPERIENCE (College of Pharmacy, University of Michigan)
04/2003-present Preceptor for Pharmacy Residents, general and specialty
2005 – 2009 Elective Clerkship 693 & 694
Pediatric Critical Care
04/2004 P486 Pharmaceutical Care II
2001-2004 P510 Pharmaceutical Care III
(Patient assignments and case presentations)
2003 Elective Clerkship 693 & 694
(P4 outpatient dialysis rotation)
2001-2001 P550 Opportunities in Pharmacy
(Postgraduate training opportunities)
1997-2001 Introductory Clerkship 685
ABSTRACTS/POSTERS
Pasko DA, Churchwell MD, Btaiche IF, Jain JC, Mueller BA. Trace Mineral
Clearance in Pediatric Patients Supported by Continuous Venovenous
Hemodiafiltration (CVVHDF). Blood Purification 2006;24:269

14
Pasko DA, Btaiche IF, Jain JC, Mueller BA, Churchwell MD. Trace Element
Clearance in Critically Ill Patients Treated with Continuous Venovenous
Hemodiafiltration (CVVHDF). Blood Purification 2006;24:268
Cornell TT, Papez KE, Smoyer WE, Brophy PD, Mottes TA, Pasko DA. Thyroid
Hormone Transmembrane Clearance During Continuous Venovenous Dialysis
vs. Hemofiltration. Blood Purifications 2006;24:269-270
Cornell TT, Papez KE, Smoyer WE, Brophy PD, Mottes TA, Pasko DA. Thyroid
Hormone Transmembrane Clearance During Therapeutic Plasma Exchange.
Blood Purification 2006;24:270-271
Churchwell MD, Pasko DA, WE Smoyer, Mueller BA. Albumin-Supplemented
Dialysate Enhances Clearance of Carbamazepine (CBZ) with In Vitro Continuous
Venovenous Hemodialysis (CVVHD). Presented at American Society of
Nephrology, 2005
Churchwell MD, Pasko DA, Grio M, Smoyer WE, Mueller BA. Albumin-
Supplemented Dialysate Does Not Enhance Clearance of Phenytoin (PHT) with
In Vitro Continuous Venovenous Hemodialysis (CVVHD). Presented at American
Society of Nephrology, 2005, Abstract # TH-PO620
Churchwell MD, Pasko DA, Smoyer WE, Mueller BA. Albumin-Supplemented
Dialysate Enhances Clearance of Valproic Acid (VPA) with In Vitro Continuous
Venovenous Hemodialysis (CVVHD). Presented at American Society of
Nephrology, 2005
Pasko DA, Grio M, Thomas S, Motttes T, Brophy PD. Methotrexate
Transmembrane Clearance During Albumin Based Continuous Venovenous
Hemodialysis. Blood Purification 2005;23:165.
Churchwell MD, Pasko DA, Mueller BA. CVVHD Transmembrane Clearance of
Daptomycin with Two Different Hemodiafilters. Presented at ICAAC in
Washington, D.C, 2004
Churchwell MD, Pasko DA, Mueller BA. CVVH Transmembrane Clearance of
Daptomycin with Two Different Hemodiafilters. Presented at ICAAC in
Washington, D.C, 2004
Pasko DA, Annich GM. Phenobarbital Pharmacokinetics of an Infant on ECMO
and CVVHD: A case report. Presented at Pediatric CRRT, Orlando, 2004
Pasko DA, Churchwell MD, Mueller BA. Duration of continuous hemofiltration
and ultrafiltrate production influence on sieving coefficient. Presented at
American College of Clinical Pharmacy, Paris 2004

15
Pasko DA, Churchwell MD, Mueller BA Influence of Time on Multi-flow 60 Filter
Life with Continuous Venovenous Hemodialysis (CVVHD). Presented at
American College of Clinical Pharmacy, Paris 2004
Pasko DA, Btaiche IF, Nakamura AT, Jain JC, Mueller BA. In-vitro clearance of
trace elements via continuous venovenous hemofiltration. J Parenter Enteral
Nutr 2004; 28:S7-8
Btaiche IF, Pasko DA, Nakamura AT, Jain JC, Mueller BA. Daily trace element
losses via continuous venovenous hemofiltration using an in-vitro model. J
Parenter Enteral Nutr 2004; 28:S6-7.
Pasko DA, Churchwell MD, Mueller BA. Development of an In vitro Model of
Continuous Renal Replacement Therapy (CRRT) Solute Removal. Blood
Purification 2004;22:236
Pasko DA, Churchwell MD, Mueller BA. Comparison of Diffusive and Convective
Clearance with AN69 and Polysulfone Hemodiafilters in CVVH and CVVHD.
Blood Purification 2004;22:242
Pasko DA, Churchwell MD, Mueller BA. Influence of Ultrafiltrate Production
Rate on Sieving Coefficient (SC) in Continuous Venovenous Hemofiltration
(CVVH). Blood Purification 2004;22:241
Pasko DA, Mottes TA, Mueller BA. Conditioning of blood prime using Diapact®
-
based CVVHD for pediatric patients. Blood Purification 2003;21:201
Mottes TA, Pasko DA, Mueller BA. Conditioning of blood prime using Prisma®
-
based CVVHD for pediatric patients. Blood Purification 2003;21:200
O’Toole J, Pasko DA, Swartz R. Citrate Anticoagulation Improves Filter
Longevity and Uninterrupted Continuous Renal Replacement Therapy in Severe
Acute Renal Failure. Blood Purification 2003;21:197
REVIEWER
2002/2003/2006 American Journal of Hospital Pharmacy
2002/2003 Annals of Pharmacotherapy
2003 The Journal of Pharmacy Technology
2003, 2008 Pediatric Critical Care
GRANTS

16
02/2008 “A Phase II Multicenter, Randomized, Double-Blind, Placebo-Controlled,
Parallel, Group Study to Determine the Pharmacodynamics of Sodium
Nitroprusside During Prolonged-Infusion in Pediatric Subjects.”
Site Primary Investigator: Thomas Shanley, MD
Site Co-Investigator: Deborah Pasko
Sponsor: National Institute of Child Health and Human Development
NICHD-2003-09-LT
Accepted 02/2008.
3% salary support
10/2007 “Sedation Management in Pediatric Patients with Acute Respiratory Failure” A
Multicenter Trial
Site Primary Investigator: Thomas Shanley, MD
Site Co-Investigator: Deborah Pasko
Sponsor: National Institute of Health, R01
Accepted 12/2007. Patient enrollment starting Spring, 2009. 3% salary support
09/2005 “Using Role-exchanging within a Multidisciplinary Triad of Health Professionals
to Improve Patient Medication Safety in a Pediatric Hospital”
Primary Investigator: Chris Dickinson, MD
Co-Investigator: Deborah A. Pasko
Sponsor: National Patient Safety Foundation
$100,000. Status: not Funded
12/2003-06/2004 “Pharmacokinetics of Cidecin During Continuous Renal Replacement
Therapy”
Primary Investigator: Bruce A. Mueller
Co-Investigator: Deborah A. Pasko
Sponsor: Cubist Pharmaceuticals
$25,715. Status: funded
04/2004-04/2005 “Trace Mineral Clearance by CRRT”
Primary Investigator: Bruce A. Mueller
Co-Investigator: Deborah A. Pasko, Imad Btaiche
Sponsor: National Kidney Foundation of Michigan
$12,361. Status: Funded
06/2002-06/2003 American College of Clinical Pharmacy Critical Care Fellowship
“Longitudinal Hemodiafilter Performance in Convective and Diffusive
Modes Using a Multiflow 60 and HF 400 Hemodiafilter”
Primary Investigator: Bruce A. Mueller, Co-Investigator: Deborah A. Pasko
Sponsor: American College of Clinical Pharmacy, Bayer Pharmaceuticals
$22,500, Status: funded
06/2002-06/2003 “Longitudinal Hemodiafilter Performance in Convective and Diffusive
Modes Using a CT-190 and F-80 Hemodiafilter”

17
01/2002-01/2003 “Longitudinal Hemodiafilter Performance in Convective and Diffusive
Modes Using a Multiflow 60 and F70NR Hemodiafilter”
Sponsor: University of Michigan College of Pharmacy Clinical Research
Resource Committee
01/2003 "In Vitro Hemodialysis Research Support"
Principal Investigator Bruce A. Mueller, Co-Investigator Deborah Pasko
Material support of a Dialog
Hemodialysis machine.
Sponsor: B. Braun Medical Inc. Bethlehem, PA
01/2003 "In Vitro Hemofiltration Research Support"
Principal Investigator, Bruce A. Mueller, Co-Investigator Deborah Pasko
Material support of a Diapact
Hemofiltration machine.
Sponsor: B. Braun Medical Inc. Bethlehem, PA
“Longitudinal Hemodiafilter Performance in Convective and Diffusive
Modes Using a Minifilter Plus Hemodiafilter”
Primary Investigators: Bruce A. Mueller, William A. Smoyer
Co-Investigator: Diane Cappellety, Deborah A. Pasko
Sponsor: Renal Research Institute
$25,000. Status: not funded.
“Development of an In Vitro Pharmacodynamic Antibiotic Model in Pediatric
Hemodialysis”
Primary Investigators: Bruce A. Mueller, William A. Smoyer
Sponsor: Renal Research Institute
$27,510. Status: not funded
“Development of an In Vitro Pharmacodynamic Antibiotic Model in
Hemodialysis”
Primary Investigators: Bruce A. Mueller
$27,093. Status: not funded

18
“Amelioration of AN69-induced bradykinin release in CRRT by blood prime pre-
dialysis”
Primary Investigator: Deborah A. Pasko
Co-Investigator: Bruce A. Mueller, Alvin Schmaier
Sponsor: Society of Critical Care Medicine
$50,000. Status: Not funded

Pasko,deborah cv.04.14 for linkedin pdf

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Similar to Pasko,deborah cv.04.14 for linkedin pdf

Similar to Pasko,deborah cv.04.14 for linkedin pdf (20)

Recently uploaded

Recently uploaded (20)

Pasko,deborah cv.04.14 for linkedin pdf